Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 infection can cause temporary hair loss due to stress, treatment drugs, psychological impact, and pandemic-related stress.

The study evaluated how alopecia areata severity relates to its psychosocial effects on patients.

Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.

During the COVID-19 lockdown, there were fewer cases of mild skin issues and more cases of stress-related skin conditions.

Telogen effluvium is a common, often temporary hair loss caused by stress and other factors, and it's hard to pinpoint and treat.

Dilated scalp capillaries might be a sign of hair loss related to COVID-19.

COVID-19 has increased hair loss, but many patients see regrowth within months.

COVID-19 vaccines can cause minor skin reactions, including those related to Bullous Pemphigoid, but these usually resolve on their own.

COVID-19 may trigger hair loss in some people.

Telogen effluvium increased globally after COVID-19, especially in Asian and Latin regions.

COVID-19 patients may experience hair loss, but it's not linked to their age or sex.

Some COVID-19 patients have different skin problems, which might be the only sign of the virus or related to other health issues.

The Covishield COVID-19 vaccine caused skin-related side effects in 1.23% of the people vaccinated in the study from India.

The COVID-19 pandemic increased the use of teledermatology to treat skin conditions in low-income areas, despite challenges like poor photo quality.

COVID-19 can cause a type of hair loss that usually starts 3-6 months after the illness, and treatment includes stress reduction and hair care products like Minoxidil.

COVID-19 may worsen hair loss, and Nourkrin® could be a safe treatment option, but more research is needed.

Some people in Saudi Arabia experienced hair loss after the COVID-19 vaccine, more often in women and those without prior hair loss.

The COVID-19 pandemic led to fewer dermatology patients, more stress-related skin conditions during the crisis, and a rise in contact dermatitis after, with ongoing concerns for public health and treatment delays.

COVID-19 can cause long-term lung, skin, and mental health problems, especially in women, people with other health issues, and those who had severe COVID-19.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

The COVID-19 quarantine in Turkey disrupted dermatological care, increased stress-related skin issues, and showed the need for psychological support and teledermatology.

Topical Minoxidil is effective for hair loss after COVID-19.

More people, especially Hispanic/Latinx, in certain NYC communities experienced temporary hair loss during the COVID-19 pandemic.

Most COVID-19 patients had lingering symptoms 60 days after leaving the hospital.

The pandemic increased stress-related skin conditions and those affected by behavior changes.

Kidney transplant patients who had COVID-19 experienced a significant drop in their quality of life due to long-lasting symptoms.

A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.

Interest in long-COVID symptoms in Japan increased with COVID-19 case peaks, especially for hair loss, cough, smell/taste issues, and headache.

Stem cell therapies, especially adipose-derived ones, show promise for treating severe COVID-19 and related conditions.

The random forest model effectively helps diagnose COVID-19 using key factors like age and symptoms.